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0955-470X/© 2018 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oKeywords: Background: Currently, there is no consensus on which treatments should be a part of standard deceased-donor
management to improve graft quality and transplantation outcomes. The objective of this systematic reviewwas
to evaluate the effects of treatments of the deceased, solid-organ donor on graft function and survival after trans-
plantation.
Methods: Pubmed, Embase, Cochrane, and Clinicaltrials.gov were systematically searched for randomized con-
trolled trials that compared deceased-donor treatment versus placebo or no treatment.
Results:A total of 33 studieswere selected for this systematic review. Eleven studieswere included formeta-anal-
yses on three different treatment strategies. Themeta-analysis onmethylprednisolone treatment in liver donors
(two studies, 183 participants) showed no effect of the treatment on rates of acute rejection. The meta-analysis
on antidiuretic hormone treatment in kidney donors (two studies, 222 participants) indicates no beneﬁt in the
prevention of delayed graft function. The remaining meta-analyses (seven studies, 334 participants) compared
the effects of 10min of ischaemic preconditioning on outcomes after liver transplantation and showed that isch-
aemic preconditioning improved short-term liver function, but not long-term transplant outcomes.
Conclusions: There is currently insufﬁcient evidence to conclude that any particular drug treatment or any inter-
vention in the deceased donor improves long-term graft or patient survival after transplantation.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Systematic review
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Management1. Introduction
Due to the persistent shortage of organs available for solid organ
transplantation [1], the transplant community has been searching for
possibilities to further expand the donor pool. One way to achieve this
is by accepting organs retrieved from older and higher risk donors,
without compromising good transplantation outcomes. Improving
quality of suboptimal organs from donors after brain death (DBD),
older expanded-criteria donors (ECD), or donors after circulatorylkaline phosphatase; AST,
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. This is an open access article underdeath (DCD) mandates better assessment and optimisation prior to
transplantation. These donors have all suffered cerebral injury, which
leads to a profound systemic inﬂammatory response [2, 3]. Further-
more, DBD and DCD donors face additional disturbances that threaten
the quality of the future organ grafts.
In DBD donors, an increased intracranial pressure impairs brain per-
fusion and causes herniation of the brain stem. This results in the release
of catecholamines and a cascade of derangements that lead to endothe-
lial dysfunction and inﬂammation in the potential grafts-to-be [4, 5]. In
addition, the function of the hypothalamus and pituitary gland becomes
impaired,which leads to decreased cortisol, triiodothyronine (T3), insu-
lin, and antidiuretic hormone (ADH) plasma levels in the donor [6, 7].
After herniation of the brain stem, a haemodynamically unstable state
will follow that requires ﬂuid resuscitation and often inotropic support.
In DCDdonors, there is no catecholamine release. Instead,withdrawal of
medical support results in a signiﬁcant blood pressure drop until circu-
latory arrest. This period of circulatory arrest is followed by a in most
countries medico-legal ﬁve-minute no-touch period prior to conﬁrma-
tion of death, which adds extra warm ischaemic injury and threatens
the quality of the potential grafts. In addition to these donor-related in-
juries, the grafts-to-be subsequently endure a period of preservation
and cold ischaemia that are further detrimental to the organ quality.
To improve transplant outcomes in solid organ transplantation, an
optimised and more organ-protective Intensive Care regimen shouldthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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important since donor age and comorbidities have increased signiﬁ-
cantly inmost countries. In deceased donor care, this has led to the con-
sideration of numerous treatment options aspiring improvement of
graft function and survival after transplantation. Unfortunately, clinical
implementation has not happened,whilst a lot of controversy still exists
about which treatment could actually beneﬁt donor organs potentially
improving transplant outcomes.
The purpose of this systematic review is to provide an update on all
systematically tested clinical interventions in the deceased donor and
their impact on graft function and/or survival following solid organ
transplantation. This review will concern any clinical treatment regi-
men that was carried out in either DBD or DCD donors using either spe-
ciﬁc drugs, ﬂuids, or procedures to reduce donor organ injury prior to
organ preservation and transplantation.2. Materials and methods
2.1. Selection criteria
RCTs or quasi-RCTs (trials inwhich the allocationmethod is not truly
random) were selected that compared differences in graft function and
survival between pre organ retrieval-treated, deceased, adult (16 years
or older) solid-organ donors (including DCD, DBD, and ECD donors) to
untreated or placebo-controlled donors. Primary outcomes for this sys-
tematic review were graft function and patient and graft survival. Sec-
ondary outcome parameters were surrogate markers of organ injury.
Exclusion criteria for this systematic review were 1. articles not in
English; 2. duplicate studies; 3. living donors; 4. average donor age b
16 years old; 5. studies with pregnant participants; 6. animal studies;
7. tissue transplantation; 8. donor treatment after graft procurement;
9. ex-situ treatment of the graft; 10. treatment of the recipient; and
11. no information on organ function or survival.2.2. Search methods for identiﬁcation of studies
This systematic review was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines [8]. Potential RCTs were identiﬁed using electronic andman-
ual search strategies. The ﬁnal electronic literature searches were per-
formed in Pubmed (5 Nov 2016), Embase (5 Nov 2016), and the
Cochrane library (7 Nov 2016). The ClinicalTrials.gov register was also
searched (7 Nov 2016) to identify unpublished or ongoing trials. The
searchwas limited to RCTswith a highly sensitive search-strategy ﬁlter.
The bibliographies of identiﬁed studies and reviews were manually
searched for additional trials. A qualiﬁed librarian reviewed the ﬁnal
search strategy. The search strategy for each consulted database is avail-
able in the supplementary data (Fig. S1, Table S1 and S2).2.3. Data extraction and validity assessment
All identiﬁed records were screened on title and abstract after re-
moval of duplicates with an algorithm provided by Refworks
(ProQuest-LCC, USA). Full articles of selected records were retrieved
and assessed for eligibility; disagreements were resolved by consensus.
Abstracts not providing information on the study type or outcome pa-
rameters were retrieved for full-text evaluation. Study information
was extracted independently by two reviewers. The risk of bias assess-
ment was performed according to the Cochrane risk of bias tool [9]. The
assessment of study quality included randomsequence generation, allo-
cation concealment, performance bias, detection bias, attrition bias,
reporting bias, and “other” bias. Quality assessments were performed
independently and disagreements were resolved through discussion.2.4. Data synthesis
Outcome parameters of interest for all transplanted solid organs
were: patient and graft survival; development of primary dysfunction,
sometimes subdivided in either primary non-function or initial poor
function; acute rejection; Intensive Care Unit (ICU) or hospital stay;
and post-operative complications (such as post-operative infections or
biliary complications, Table 1). Organ-speciﬁc parameters of interest
were: creatinine clearance, serum creatinine, and delayed graft function
(DGF, measured as the need for renal replacement therapy including
haemodialysis (HD) or haemoﬁltration (HF) in theﬁrstweek post trans-
plantation) (kidney); aspartate transaminase (AST), alanine amino-
transferase (ALT), albumin, alkaline phosphatase (AF), bilirubin,
gamma-glutamyl transpeptidase (ɣGT), and lactate dehydrogenase
(LDH) levels, and International Normalised Ratio(INR) (liver); left ven-
tricular function, and left ventricular assist device (LVAD) and HF re-
quirement (heart); and PaO2/FiO2 ratio, compliance (plateau pressure
at the end of respiration), and organ utilization rates as an indirect
way of assessing graft function (lung). Qualitative assessment was per-
formed for single studies that could not be grouped for meta-analyses.
For studies that could be grouped, a forest plotwas constructed to assess
the heterogeneity, using Cochran's Q test and the I2-test (considered
signiﬁcant when p b .1 or I2 N 30%). A random-effects analysis model
was applied, followed by theMantel-Haenszel test to calculate cumula-
tive relative risk ratios for dichotomous variables. As no more than four
studies were included per meta-analysis, funnel plot analyses could not
be constructed to distinguish potential asymmetry. All statistical analy-
ses were performed with ReviewManager v5.3 (The Cochrane Collabo-
ration 2014).
3. Results
3.1. Literature search and summary of included studies
From 7309 hits in total, 62 studies were assessed. As 29 studies
failed to meet our inclusion criteria, a total of 33 articles were in-
cluded in this systematic review (Fig. 1, Table 1, Table S3). Even
though the search strategy was aimed towards all solid organs,
only studies on kidney, liver, heart, and lung transplantations were
found. In addition, we identiﬁed 13 trials that were still ongoing or
did not yet publish results (Table 2). As none of the included studies
involved interventions in DCD donors, this systematic review de-
scribes only trials in DBD donors.
The following treatment strategies for DBD donors were identiﬁed:
anti-oxidant treatment [10–13], enteral feeding [14], organ retrieval
techniques [15, 16], haemodynamic support [17–24], mild therapeutic
hypothermia (MTH) [25], immunosuppressants [26–31], ischaemic pre-
conditioning (IPC) [32–39], a lung protection strategy [40, 41], and T3
administration [42]. Table 1 shows a summary of these included studies,
while Table S4 shows the risk of bias for these trials. In 16 studies, the
methods for patient selection and allocation concealment were ade-
quately performed and described. Eight studies used a placebo-con-
trolled group, whereas the remaining studies had either non-
treatment groups (n = 20) or compared the intervention to a conven-
tional treatment (n = 5).
3.2. Studies that could not be included for meta-analyses
Twenty-two studies [10–18, 21–28, 31, 32, 40–42] were not in-
cluded for meta-analyses because the type of intervention or outcome
parameter could not be compared to other trials included in this review.
None of the studies reported a signiﬁcant effect of the treatment or in-
tervention on ICU or hospital stay.
Four studies tested effects of anti-oxidant treatments in DBD do-
nors on graft function [10–13]. Treatments with N-acetylcysteine
[12] and L-alanyl-glutamine [10] showed no effects following kidney
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treatment [11] and donor ventilation with sevoﬂurane [13] showed
improved short-term liver function but did not report effects on pa-
tient or graft survival.
Two trials investigated two different hepatic retrieval techniques.
Chui et al. [15] showed no differences between single (aortic) or double
(aortic and portal) perfusion on liver and kidney transplantation out-
comes, whilst D'Amico et al. [16] showed superiority of the double per-
fusion technique, evidenced by improved short-term liver function,
lower rates of re-transplantation, and improved six-month graft and pa-
tient survival.
Six out of eight studies on hemodynamic support of the deceased
donor could not be grouped for meta-analyses [17, 18, 21–24]. Dopa-
mine treatment improved long-term graft survival after heart [18], but
not kidney transplantation [17], despite a reduced incidence of DGF of
renal organ grafts [17]. Prostaglandin I2 treatment improved short-
term liver function, but failed to improve patient or graft survival [21].
Protocolised ﬂuid administration did not alter recipient survival after
solid organ transplantation [22]. The use of the colloid hydroxyl-ethyl
starch (HES) (of unknown molecular weight) did not affect liver func-
tion following transplantation [23]; treatment with low molecular
weight-HES did increase rates of DGF following renal transplantation
[24].
Four out of six trials on the use of immunosuppressive drugs could
not be clustered. Administration of neither methylprednisolone and cy-
clophosphamide [27, 28], nor cyclophosphamide [31], nor prednisolone
[26] improved renal transplantation outcomes.
Of the seven studies found on IPC treatment in liver donors, the only
study investigating ﬁve minutes of IPC showed no beneﬁts following
liver transplantation.
The remaining trials investigated possible clinical beneﬁts of enteral
feeding [14], MTH [25], albuterol [41] or T3 [42] administration, and a
protective lung ventilation strategy [40]. Neither enteral feeding [14],
nor albuterol administration [41], nor protective lung ventilation [40]
improved survival rates of recipients after heart, lung, liver, or kidney
transplantations. MTH decreased the incidence of DGF after kidney
transplantation [25]. Lastly, T3 administration did not improve liver
function following transplantation [42].3.3. Studies included for meta-analyses
Eleven studieswere identiﬁed for furthermeta-analyses. Noneof the
studies that were included for meta-analyses reported a signiﬁcant ef-
fect of the treatment or intervention on ICU or hospital stay. The
meta-analysis on the effects of donor treatment with ADH included
222 participants [19, 20] and showed no difference in the development
of DGF after kidney transplantation between treated and untreatedDBD
donors (Fig. 2).
The meta-analysis on donor methylprednisolone treatment versus
placebo or no treatment included a total of 183 participants [29, 30]
and showed similar acute rejection rates of liver grafts retrieved from
donors treated either with or without methylprednisolone (Fig. 3).
Ten meta-analyses were included on the effects of 10 min of IPC
versus no treatment in the liver, with a total of 335 participants
from seven trials [33–39]. Results show that IPC treatment did not
inﬂuence one-year (Fig. 4A,B) or two-year graft and patient survival
(Fig. S1A,B). In the short-term, IPC treatment improved AST levels
on day one and international normalised ratio (INR) levels on day
three after surgery (Fig. 5A,C), but did not affect INR (Fig. 5B) or bil-
irubin levels (Fig. S1E) one day post-operatively. Also, the incidence
of primary non-function or initial poor function was not different
between treated and untreated grafts (Fig. S1C,D). The risk of bias
for included studies is described in Table S4. In general, the studies
included in the meta-analyses were judged to have a relatively high
risk of bias.4. Discussion
This systematic review provides an update on the existing evidence
of treatments that were applied to deceased organ donors and aimed to
improve graft quality and survival after kidney, liver, heart, and lung
transplantations. Our meta-analyses found no consistent evidence to
support that any speciﬁc donor-management strategy or treatment in
DBD donors beneﬁted outcomes after transplantation (see Fig. 6 for an
overview of all included studies per organ). This ﬁnding is in line with
previous and older reviews published on this topic [43–47].
4.1. Anti-oxidants
Brain death and IRI are associated with increased levels of reactive
oxygen species (ROS),whichplay a central role in the deleterious effects
following transplantation [48]. Therefore, the use of anti-oxidants to
scavenge ROS or support cellular detoxiﬁcation appears to be an intui-
tively sound strategy to limit IRI. However, none of the four compounds
tested improved survival rates following kidney (N-acetylcysteine) [12]
or liver (L-alanyl-glutamine, ascorbic acid, sevoﬂurane) [10, 11, 13]
transplantation, even though ascorbic acid [11] and donor ventilation
with sevoﬂurane [13] improved short-term liver function. In addition,
Minou et al. showed that sevoﬂurane did have protective effects inmar-
ginal livers with various degrees of hepatic steatosis [13]. Recently, a
RCT on simultaneous kidney and pancreas transplantations showed
that treatment with 600 mg alfa-lipoic acid in both donors and recipi-
ents resulted in decreased inﬂammatory markers in the transplanted
grafts [49]. These promising results may encourage more trials with
anti-oxidant treatment strategies, either in the donor, during graft pres-
ervation or at time of reperfusion.
4.2. Enteral feeding
For critically ill patients, enteral feeding is the preferred route for nu-
tritional support [50]. However, nutritional support is usually withheld
in DBDdonors due to suggested negative side effects of both enteral and
parenteral feeding. Negative effect of enteral feeding are thought to be
impaired nutritional uptake as a result of the inﬂammatory response
taking place in the bowel of DBD donors [51]. Alternatively, parenteral
feeding is related to metabolic, infectious, and mechanical complica-
tions [52]. The only RCT on this topic compared fasting of the DBD
donor to enteral feedingwith a diet containing fatty acids, antioxidants,
and glutamine. This study shows that transplant outcomes and inﬂam-
matory parameters were not different between groups following on av-
erage 12.6 h of enteral feeding [14]. Effects of nutritional duration were
not investigated. As about 30%of the donorswere able tometabolise en-
teral nutrition without negative side effects [14], enteral feeding ap-
pears to be safe method for nutritional support in DBD donors.
4.3. Organ retrieval techniques
During organ procurement, there are two techniques to ﬂush-out
and perfuse the liver graft. The classic, dual perfusion technique ﬂushes
the graft via both the aorta and portal vein [53]. Alternatively, most cen-
tres nowuse single aortic perfusion as an simpliﬁed, alternativemethod
that is of particular interest during multiple organ harvesting or split
liver transplantation [16], followed by additional back-table ﬂush of
the liver. The two RCTs that compared these techniques show conﬂict-
ing results [15, 16]. Chui et al. [15] found no differences between the
techniques following liver and kidneys transplantation, while D'Amico
et al. [16] found an improved function of marginal livers after dual per-
fusion. Unfortunately, it is challenging to draw conclusions from these
studies: Chui et al. did not provide a full report on their study design,
whilst D'Amico et al. focused primarily on marginal donors, which
makes extrapolation of these results to the general donor population
Table 1
Summary of randomized controlled trials of interventions in deceased organ donors.
Intervention type Source Year Number of
patients
randomized
Treatment group
(administration mode and
timE.
Control group Outcome
(subgroup)
Speciﬁc end-points (time after
transplantation)
Effect organ function (treatment vs. control
group)
Effect
patient/graft
survival
Anti-oxidants Orban et al.
[12]
2015 217 600 mg N-acetylcysteine
(bolus, 1 h before and 2 h
after angiography)
No treatment Kidney
function
sCr and eGFR (D1,7,14,30); DGF (HD
requirement/ oliguria/ sCr N500 μmol/L,
D0–7); acute rejection (D0–30); patient
and graft survival (≤Y1); and recipient
hospital stay
No No (graft)
Barros et al.
[10]
2015 33 50 g L-alanyl-glutamine
(bolus, 40 min before cold
ischaemia)
Placebo Liver
function
AST, ALT, bilirubin, INR (D0,1,3,7,30);
patient and graft survival (duration
unknown)
No No (patient
and graft)
Kazemi et al.
[11]
2015 40 100 mg/kg ascorbic acid
(bolus, 6 h before
procurement) and
subsequent 100 mg/kg/p6h
(infusion, until procurement)
No treatment Liver
function
AST, ALT, bilirubin (D1,3,10) Positive - AST and ALT on D3 vs. D1 (data not
speciﬁed)
Not
measured
Minou et al.
[13]
2012 60 2.0% sevoﬂurane (end
expiratory, during
procurement)
No treatment Liver
function
(degree of
steatosis)
Peak ALT, AST (D0–2); PNF, IPF (bilirubin
≥10 mg/dL, INR ≥ 1.6, AST/ALT ≥2000 IU/L,
D0–7); and recipient ICU/hospital stay
Positive - Peak AST: 792 vs. 1861 IU/L - IPF: 17
vs. 50%
Not
measured
Enteral feeding Hergenroeder
et al. [14]
2013 36 Enteral nutrition containing
omega-3-PU FA,
anti-oxidants, glutamine (1 g
protein/kg per 24 h, until
procurement)
No treatment Survival Patient and all solid organ-graft survival
(M0–6)
Not measured No (patient
and graft)
Organ retrieval
techniques
Chui et al. [15] 1998 40 Single aortic perfusion Double
perfusion
(aortic and
portal)
Kidney and
liver
function
AST, ALT, INR (D1–2); PNF; patient and
graft survival (≤M3)
No No (patient
and graft)
D'Amico et al.
[16]
2007 58 Double perfusion (aortic and
portal)
Single aortic
perfusion
Liver
function
AST, ALT, bilirubin, INR
(D1–3,5,7,M1,3,6,9,12); PDF (PNF + IPF,
≤D7); patient and graft survival (≤M6); and
re-transplantation
Positive - AST: 763 vs. 2125 IU/L, D2 - ALT:
614 vs. 1580 IU/L, D2 -PDF: 6 vs. 41% -
Re-transplant: 0 vs. 5
Positive -
patient: 100
vs. 68% -
graft: 100 vs.
58%
Haemo-dynamic
support
Benck et al.
[18]
2011 264 4 μg/kg/min dopamine
(infusion, after consent until
procurement)
No treatment Heart
function
LVF, LVAD and HF requirement; acute
rejection (M0-M1); patient and graft
survival (≤M3, Y1,2,3)
No Positive
(patient and
graft) - 91 vs.
72%, Y1 - 87
vs. 68%, Y3
Pennefather et
al. [19]
1995 24 300 μg/kg/min arginine
vasopressin (infusion, when
haemodynamically stable
after BD conﬁrmation)
Placebo Heart,
kidney,
liver, lung
function
Good initial function: - kidney: DGF -
liver/lung: unclear - heart: inotropics
requirement
No Insufﬁcient
data reported
Schnuelle et al.
[17]
2009 264 4 μg/kg/min dopamine
(infusion, after consent until
procurement)
No treatment Kidney
function
(infusion
and CI
time)
sCr, DGF (dialysis requirement) (D0–7);
acute rejection (≤M1); patient and graft
survival (≤Y3)
Positive - DGF: 25% vs. 35% - DGF subgroup
long vs. short infusion time: 21% vs. 36%
No (patient
and graft)
Guesde et al.
[20]
1998 97 1 μg desmopressin (bolus,
every 2 h when diuresis b300
mL/h after consent until 2 h
before procurement)
No treatment Kidney
function
sCr, DGF (HD requirement) (D0–15);
survival (≤Y5)
No No
Cittanova et al.
[24]
1996 27 LMW Hydroxyethyl-starch
up to 33 mL/kg with
additional ﬂuid gelatin when
Placebo Kidney
function
DGF (HD/HF, D1–8), sCr (D1,2,5,10) Negative Not
measured
(continued on next page)
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Table 1 (continued)
Intervention type Source Year Number of
patients
randomized
Treatment group
(administration mode and
timE.
Control group Outcome
(subgroup)
Speciﬁc end-points (time after
transplantation)
Effect organ function (treatment vs. control
group)
Effect
patient/graft
survival
needed
Klein et al. [21] 1999 112 500 μg prostaglandin I2
(bolus, before procurement)
No treatment Liver
function
AST, ALT, bilirubin, GLDH, AF, γGT (D0–28);
PNF; in-hospital survival; vascular
thrombosis, and recipient ICU/hospital stay
Positive - AST/ALT, D0,1 - GLDH, D1–4 No (patient
and graft)
Randell et al.
[23]
1990 16 500 mL 6%
hydroxyethyl-starch and
additionally 1000 mL when
CVP b5 mmHg and
crystalloids (infusion, before
procurement)
Crystalloids Liver
function
PNF No Not
measured
Al-Khafaji et al.
[22]
2015 556 Protocolised resuscitation
using a consensus-based
pulse pressure variation
algorithm (until
procurement)
Standard donor
management
Recipient
survival
(ECD
donors)
Number of transplanted organs per donor,
recipient (hospital free) survival (≤M6)
Not measured No (patient)
Mild therapeutic
hypothermia
Niemann et al.
[25]
2015 394 Mild therapeutic
hypothermia (34–35 °C, after
declaration of BD until
procurement)
Normothermia
(36.5–37.5 °C)
Kidney
function
(ECD
donors)
DGF (dialysis requirement D0-D7) Positive - DGF: 28.2% vs. 39.2% - DGF
subgroup ECD vs. SCD: 31% vs. 57%
Not
measured
Immuno-suppressants Kainz et al.
[26]
2010 306 1000 mg
methylprednisolone (bolus, ≥
3 h before procurement)
Placebo Kidney
function
(donor
age≤/N50)
SCr, DGF (D0–7) No No (graft)
Chatterrjee et
al. [31]
1981 50 60 mg/kg cyclophosphamide
(infusion, t ≥ 4 h before
procurement when possible)
No treatment Kidney
function
Graft failure (≤Y1) Not measured No (graft)
Soulillou et al.
[27]
1979 34 5 g methylprednisolone and
5 g cyclophosphamide
(infusion, t ≥ 5 h before
procurement)
Placebo Kidney
function
SCr, graft survival, (M3,6,12) No No (graft)
Jeffery et al.
[28]
1978 Unclear 5 g methylprednisolone and
7 g cyclophosphamide
(infusion, t ≥ 4 h before
procurement when possible)
No treatment Kidney
function
sCr, rejection, patient and graft survival
(M3,6,12)
No No (patient
and graft)
Amatschek et
al. [29]
2012 83 1000 mg
methylprednisolone (bolus,
between 3 and 6 h before
procurement)
Placebo Liver
function
AST and ALT (D0–7); rejection, patient and
graft survival (≤Y3); bile duct
complications, recipient ICU/hospital stay
No No (patient
and graft)
Kotsch et al.
[30]
2008 100 250 mg methylprednisolone
(bolus at consent +100 mg/h
IV until procurement)
No treatment Liver
function
AST, ALT, bilirubin, AF, ɣGT (D0–10); acute
rejection (AR), PNF (≤M6); and biliary
lesions
Positive - AST: 327 vs. 1470 / ALT:461 vs. 758
/ AP: 127 vs. 157 / ɣGT: 135 vs. 236 (D1) -
AST: (31 vs. 41 / ALT: 75 vs. 115 / bilirubin:
2.3 vs. 4.9(D10) - Bilirubin: 0.6 vs. 1.0 (M6) -
AR: 22% vs. 36%, M6
No (graft)
Ischaemic pre-
conditioning
Zapati-Chavira
et al. [39]
2015 13 10 min IPC (hilar clamping,
followed by 10 min
reperfusion before
procurement)
No treatment Liver
function
AST, ALT, bilirubin, INR (D1,3,7); PNF, IPF;
patient and graft survival (M6, 24); and
recipient ICU stay
Slightly negative - Bilirubin: 3.5 vs. 1.6 mg/dL No
Cescon et al.
[35]
2009 40 10 min IPC (hilar clamping,
followed by 15 min
reperfusion before
procurement)
No treatment Liver
function
AST, ALT, bilirubin, INR (D1–7, 14, 21); PNF,
IPF; patient and graft survival (Y0-Y1), and
recipient ICU stay
No No
Franchello et
al. [38]
2009 75 10 min IPC (hilar clamping,
followed by 30 min
reperfusion before
procurement)
No treatment Liver
function
AST, ALT, bilirubin, INR (D1,3,7); acute
rejection, PNF; graft survival (M6);
infections (M1), and recipient hospital stay
Slightly positive for subgroup marginal grafts:
- AST: 936 vs. 1268 (D1), 339 vs. 288 (D3),
UI/L
No
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Jassem et al.
[37]
2009 44 10 min IPC (hilar clamping,
followed by (on average) 30
min reperfusion before
procurement)
No treatment Liver
function
AST (D1–5); bilirubin and INR (D7, 14,30);
acute rejection
Slightly positive - AST: 410 vs. 965 (D1), 198
vs. 488 (D2), 120 vs. 216 (D3) IU/L
Not
measured
Koneru et al.
[33]
2007 101 10 min IPC (hilar clamping,
followed by median of 39
min reperfusion before
procurement)
No treatment Liver
function
(marginal
grafts)
AST, ALT, bilirubin, INR (D1–3,7,14,30);
injury score (biopsy); acute rejection
(D0–30); PNF; patient and graft survival
(≤Y2); blood transfusions; lung edema, and
recipient ICU/hospital stay
Negative - AST: 385 vs. 250 IU/L, D2 - ALT:
699 vs. 520 (D1), 583 vs. 353 (D2) IU/L
No (patient
and graft)
Amador et al.
[36]
2007 60 10 min IPC (hilar clamping,
followed by 10 min
reperfusion before
procurement)
No treatment Liver
function
AST, ALT, bilirubin, INR (D1–10); PNF
(D0–7); acute rejection; patient (Y2,Y4)
and graft survival (2Y); vascular and biliary
complications, and recipient ICU/hospital
stay
Positive - AST: 894 vs. 1216 (D0), 918 vs.
1322 (D1), 500 vs. 756 (D2), 201 vs. 344 (D3),
120 vs. 170 (D4) U/L - ALT 671 vs. 1216 (D0),
235 vs. 304 (D7) U/L - Bilirubin 2.5 vs. 3.6
mg/dL (D1)
No (patient
and graft)
Cescon et al.
[34]
2006 53 10 min IPC (hilar clamping
followed by 15 min
reperfusion before
procurement)
No treatment Liver
function
AST, ALT, bilirubin, INR (D1-D7,D14,D21);
injury score (biopsy); PNF and IPF; patient
and graft survival (≤Y1); recipient ICU stay
Positive - AST (D1,2) - ALT (D1–3,7) Exact
numbers not given
No (patient
and graft)
Koneru et al.
[32]
2005 62 5 min IPC (hilar clamping
followed by N30 min
reperfusion before
procurement)
No treatment Liver
function
AST, ALT, bilirubin, INR (D1,3,7); injury
score (biopsy); PNF; patient and graft
survival (≤M6); and recipient hospital stay
No No (patient
and graft)
Lung protection
strategies
Ware et al. [41] 2014 506 5 mg q4h albuterol sulphate
(nebulization every 4 h, from
study enrolment until
procurement)
Placebo Lung
function
(marginal
grafts)
PaO2/FiO2, static compliance;
lung/kidney/heart/pancreas utilization
rates; patient survival (D30, ≤Y1); and
recipient hospital stay
Slightly negative - Lung utilization (marginal
grafts): 9% vs. 20% - Kidney utilization: 77 vs.
88%
No (patient)
Mascia
et al. [40]
2010 118 Protective ventilation
strategy (TV 6–8 mL/kg and
PEEP 8–10 cm, during 6 h
observational period until
organ procurement)
Conventional
ventilation
strategy (TV
10–12 mL/kg
and PEEP 3–5
cm)
Survival Patient survival (≤M6) Not measured No (patient)
Thyroid hormone Randell et al.
[42]
1992 25 2 μm/h triiodothyronine
(infusion, at start
procurement)
No treatment Liver
function
Max. ALAT, bilirubin, albumin (D0–7); and
recipient ICU/hospital stay
No Not
measured
ALT: Alanine Aminotransferase; AP: Alkaline Phosphatase; AR: Acute Rejection; AST: Aspartate Aminotransferase; BD: Brain Death; CI: Cold Ischaemia; D: Day; ECD: Extended Criteria Donor; eGFR: Estimated Glomerular Filtration Rate; ɣGT: gamma-
glutamyl transpeptidase; HD: Haemodialysis; HF: Haemoﬁltration; INR: ICU: Intensive Care Unit; International Normalised Ratio; IPF: Initial Poor Function; LVAD: Left Ventricular Assist Device; LVF: Left Ventricular Function;M:Month; PDF: Primary
Dysfunction; PNF: Primary Non-Function; SCD: Standard Criteria Donor; sCr: Serum Creatinine; Y: Year.
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Fig. 1. PRISMA diagram of the literature search. Flow chart summarising the search strategies and subsequent selection of trials for this systematic review and the performed meta-
analyses.
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superiority of either perfusion technique.
4.4. Haemodynamic support
Diabetes insipidus is a common ﬁnding amongst DBD donors and
may cause haemodynamic instability in the donor due to hypovolaemia
and electrolyte disturbances [20]. However, treatment strategies to im-
prove haemodynamic instability in the donor are frequently based on
personal experience as there is no general consensus onwhat treatment
is most effective.
Treatment of hypovolaemia with crystalloids has been suggested to
cause organ oedema, diminished organ perfusion, and impaired oxygen
diffusion in the lungs. Therefore, the use of colloids was introduced to
avoid this build-up of extravascular ﬂuids. In DBD donor care, two
RCTs studied the effects of donor treatment with the colloid HES. The
study by Randell et al. [23] showed no difference in graft function
after the administration of HES (unknownmolecularweight) compared
to saline prior to liver transplantation. However, treatment of DBD do-
nors with lowmolecular weight HES resulted in harmful short-term ef-
fects in kidney grafts [24]. This result has led to the notion that HES
should not be administered to potential kidney donors. However, it
should be noted that both studies have a high risk of bias, which may
have inﬂuenced the results and possibly their interpretation. A different
approach to achieve donor euvolaemia is to monitor the pulse pressure
variation and correct hypotension according to a protocol that includes
ﬂuid or vasopressive drug administration [22]. However, implementa-
tion of this protocol failed to improve the recipient survival rate or num-
ber of organs transplanted per donor.
Alternatively, ﬁve RCTs tested the effects of pharmaceuticals as a
means to provide haemodynamic support. Firstly, administration of
ADH did not improve graft function (Fig. 2), but did result in decreased
urine output and, therefore, the need forﬂuid therapy. Secondly, admin-
istration of dopamine in DBD donors had a positive effect on short-term
renal graft function [17], whilst in heart transplantation it improvedlong-term graft and patient survival [18]. Finally, administration of
prostaglandin I2 improved transaminase levels immediately and one
day after liver transplantation, but failed to improve graft survival [21].
In conclusion, unstable haemodynamic parameters should be
treated appropriately with volume replacement and haemodynamic re-
suscitation. However, volume replacement with HES should be used
with caution, especiallywhen kidney donation is considered. Haemody-
namic support using dopamine appears to be beneﬁcial in heart and
possibly in kidney transplantation. Thus, further studies on the use of
dopamine as part of standard donor care and its effects on other organ
grafts is desirable.4.5. Hypothermia during donor management
Promising results published by Niemann et al. show that MTH of the
deceased donor (cooling of the donor from 37 °C to 34–35 °C at the In-
tensive Care Unit) preserved kidney function during donor manage-
ment in the Intensive Care Unit, with decreased DGF rates after
transplantation. These results are in line with a retrospective cohort
study on patients with a myocardial infarction, for whom MTH treat-
ment prior to and during their percutaneous coronary intervention im-
proved survival rates and preserved renal function [54]. However, these
protective effects of MTH could not be reproduced in RCTs on patients
with cardiac arrests [55, 56] or intracranial aneurysms [57]. Long-term
effects of MTH treatment are eagerly awaited before implementation
of this technique can be considered as standard donor care [25]. Fur-
thermore, the study by Niemann only included statically cold-stored
kidneys, whilst hypothermic machine perfusion has demonstrated to
signiﬁcantly reduce DGF and improve graft survival, especially in older
and higher-risk donor kidneys [58]. Therefore, the question arises
whether both treatment regimens are necessary and which one is
more cost-effective. Recently, a new trial has started that will compare
the effects of donor MTH with hypothermic machine perfusion on
graft function after transplantation62.
Fig. 2.Meta-analysis for antidiuretic hormone treatment in kidney transplantation. A forest plot comparing the effects of antidiuretic hormone treatment versus placebo or no treatment
on delayed graft function, deﬁned as the need for haemodialysis within two weeks post-kidney transplantation.
Table 2
Identiﬁed studies that are still recruiting or have not yet published results.
Trial id Investigator Treatment Participants Start
inclusion
Stop
inclusion
Title Sponsor
NCT02581111 Dhar Naloxone 250 2015 2016 Randomized Placebo-controlled Trial of Intravenous Naloxone
to Improve Oxygenation in Hypoxemic Lung-Eligible
Brain-Dead Organ Donors
Washington Univer-
sity School of
Medicine, USA
NCT02435732 Fernandez C1 inhibitor 72 2016 2018 A Phase I, Single Center, Randomized, Double-Blind,
Placebo-Controlled Study to Evaluate Tolerability of C1
Inhibitor (CINRYZE) as a Donor Pretreatment Strategy in
Brain-Dead Donors Who Meet a Kidney Donor Risk Index
(KDRI) Above 85%
University of
Wisconsin, Madison,
USA
NCT02211053 Frenette Levothyroxine 60 2014 2016 Evaluation of the Efﬁcacy and Safety of Levothyroxine in Brain
Death Organ Donors: a Randomized Controlled Trial
(ECHOT4)
Hopital du
Sacre-Coeur de
Montreal, Canada
NCT01860716 García-Gil Melatonin 60 2013 2013 Impact of Melatonin in the Pretreatment of Organ Donor and
the Inﬂuence in the Evolution of Liver Transplant: a
Prospective, Randomized Double-blind Study
Hospital Clínico
Universitario Lozano
Blesa, Spain
NCT02907554 Ichai Cyclosporine A 648 2016 2018 Effects of Cyclosporine A Pretreatment of Deceased Donor on
Kidney Graft Function: A Randomized Controlled Trial
University Hospital,
Clermont-Ferrand,
France
NCT01939171 Jiminez Thymoglobulin 20 2010 2013 Conditioning of the Cadaver Donor by Thymoglobulin
Administered to Reduce the Pro-inﬂammatory State After
Brain Death.
Instituto de
Investigación
Hospital
Universitario La Paz,
Spain
NCT01160978 Jokinen Simvastatin 46 2010 2015 Donor Simvastatin Treatment in Organ Transplantation Helsinki University
Hospital, Finland
NCT02341833 Joris 2% sevoﬂurane 240 2015 2017 Effects of Preconditioning With Sevoﬂurane During Organ
Procurement From Brain-Dead Donors: Impact on Early
Function of Liver Allografts
University Hospital of
Liege, Belgium
NCT00975702 Koneru Remote ischaemic
preconditioning
85 2009 2014 Phase III Study of Efﬁcacy of Remote Ischaemic
Preconditioning in Improving Outcomes in Organ
Transplantation (RIPCOT)
The State University
of New Jersey, USA
NCT01515072 Koneru and
Washburn
Remote ischaemic
preconditioning
320 2011 2014 Remote Ischaemic Preconditioning in Neurological Death
Organ Donors (RIPNOD)
The State University
of New Jersey, USA
NCT01140035 Niemann Intensive insulin
treatment
200 2009 2011 Intensive Insulin Therapy in Deceased Donors - to Improve
Renal Allograft Function and Transplanted Allograft Outcomes
University of
California, San
Francisco, USA
NCT02525510 Niemann Hypothermia/
normothermia and
static cold
storage/machine
perfusion
500 2015 2019 Deceased Organ Donor Interventions to Protect Kidney Graft
Function
University of
California, San
Francisco, USA
NCT00718575 Selzner Ischaemic
preconditioning
50 2008 2012 A Prospective, Randomized Trial to Investigate the Effects of
Glucose/ Ischaemic Preconditioning Donor Pretreatment on
Reperfusion Injury in Deceased-Donor Liver Transplantation
University Health
Network, Toronto,
Canada
Fig. 3.Meta-analysis formethylprednisolone treatment in liver transplantation. A forest plot comparing the effects ofmethylprednisolone treatment versus placebo or no treatment on the
incidence of acute rejection within one to six months after liver transplantation.
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Fig. 4.Meta-analyses for the effect of ischaemic preconditioning (IPC) treatment on survival. Forest plot comparing the effects of 10 min of IPC treatment during liver transplantation: A.
one-year graft survival and B. one-year patient survival.
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Brain death results in pro-inﬂammatory changes, both systemically
and in the organ grafts [4]. Additionally, endogenous cortisol levels de-
crease after the onset of brain death [59, 60]. Therefore, it is conceivable
that donor treatment with immunosuppressive drugs could prevent
pro-inﬂammatory changes and improve graft quality, as was suggested
in experimental animal studies [61, 62] and a large retrospective cohort
study [63]. However, our meta-analysis on the effects of prednisoloneFig. 5.Meta-analyses for the effect of ischaemic preconditioning (IPC) treatment on liver functi
the difference in AST levels one day after transplantation, B. the difference in INR levels one datreatment showed no changes in the frequency of acute rejection fol-
lowing liver transplantation (Fig. 3). Furthermore, immunosuppressive
drug treatment did neither improve long-term graft function, nor pa-
tient, nor graft survival following kidney and liver transplantation
[26–31], despite a decrease in DBD-related pro-inﬂammatory changes
in these organs. In addition, the one study that investigated the effects
of immunosuppressive therapy in marginal donors (higher donor
age), found no differences in kidney function or graft survival [19]. Fi-
nally, the short-term beneﬁts of prednisolone treatment in liver grafton. Forest plot comparing the effects of 10 min of IPC treatment in liver transplantation: A.
y after transplantation, and C. the difference in INR levels three days after transplantation.
Fig. 6. Overview of all systematically tested, clinical treatments or interventions in the
brain-dead donor with outcome parameters pertaining the lungs, liver, heart, and
kidneys. Treatments or interventions denoted in black did not affect graft function or
graft and patient survival. Treatments or interventions denoted in green were beneﬁcial,
those in red were detrimental, and those in orange inconclusive.
203A.C. van Erp et al. / Transplantation Reviews 32 (2018) 194–206as observed by Kotsch et al. [30], could not be reproduced in a similar
study by Amatschek et al. [29]. In conclusion, these studies do not sup-
port the routine use of methylprednisolone alone, or in combination
with cyclophosphamide, in the management of DBD donors.
4.7. Ischaemic preconditioning
Ischaemia-reperfusion injury (IRI) is an unavoidable deleterious
process during organ transplantation. Initially, the organs suffer from a
period of ischaemia during procurement, followed by injury during sub-
sequent reperfusion in the recipient. Murry et al. ﬁrst introduced the
concept of IPC as a method to induce transient ischaemia, preparing
the organs for subsequent IRI [64]. We identiﬁed eight studies on IPC,
all performed prior to liver transplantation. Pooled data from our
meta-analyses shows a short-term beneﬁt of ten-minute IPC treatment
that seems independent of theduration ofwarm ischemia, evidenced by
improved post-operative AST and INR levels. Even though long-term ef-
fects on patient and graft survival were lacking and the different studies
showed some conﬂicting results, data from our meta-analysis highly
suggests a potential beneﬁt of IPC prior to liver transplantation, particu-
larly as AST levels in the ﬁrst week after transplantation have been cor-
related to early graft survival (b3months) [65]. The RCT by Franchello etal. reported improved AST levels in a subgroup of marginal donors
(N65 years old and/or with steatosis) [38]. Further studies powered to
detect changes in short-term survival rates and adjusted for graft qual-
ity should be performed to elucidate whether IPC should be included in
standard donor care. Furthermore, there are currently several on-going
trials investigating remote IPC, a technique where (repetitive) cycles of
ischaemia are applied to a remote organ or tissue such as a limb with,
consequentially, a possible wider therapeutic timeframe in the donor
(Table 2).4.8. Lung protection strategies
DBDdonors are at increased risk of pulmonary damage caused by in-
creased pulmonary hydrostatic pressure, catecholamine release, and
pro-inﬂammatory changes [66]. However, the optimal lung ventilation
strategy in decreased donor care has been a topic of controversy [67].
Conventionally, high tidal volumes (TV) (10–12 mL/kg) were applied,
ensuring hypocapnia and a decrease in intracranial hypertension, and
combined with low positive end-expiratory pressures (PEEP) (3–5 cm
H2O) to provide optimal oxygenation [66]. Recent studies on patients
with the acute respiratory distress syndrome support an alternative
strategy with a low TV and high PEEP, as this strategy appears to have
improved outcomes of acute lung injury by reducing ventilation re-
lated-injury and preventing atelectasis [66, 68]. Based on these studies,
Mascia et al. studied this protective ventilation strategy with low TV
(6–8 mL/kg) and high PEEP (8–10 cm H2O) in DBD donor care [66].
Even though this ventilation strategy did not improve patient survival,
there was a signiﬁcant increase (27–54%) in the number of lungs
transplanted [40]. These data have supported the implementation of
this protective lung ventilation strategy as the preferred ventilation
strategy for deceased donors, according to the recent guidelines from
the Eurotransplant region as well as the American Thoracic Society
[69, 70].
An alternative strategy to protect the lungs is the use of beta-2-ad-
renergic agonists, which increase the rate of ﬂuid clearance from the
lungs, potentially lowering the risk of pulmonary oedema and subse-
quent inﬁltrates, and improving oxygenation capacity [71]. However,
treatment of the donor with aerosolised albuterol did not improve
lung function, recipient survival, or lung utilization rates [41]. A sub-
group analysis of marginal donor lungs only even indicated lower lung
utilization in the albuterol-treated group. Finally, albuterol treatment
resulted in a lower kidney utilization rate of 77% vs. 88% in the pla-
cebo-treated group. As such, donor treatment with albuterol does not
seem to improve lung function andmay have a negative impact onmar-
ginal donor lungs as well as kidney grafts.4.9. Triiodothyronine
Brain death causes ischaemia of the brain and subsequent cessation
of the hypothalamic-pituitary axis. As a result, plasma levels of the ac-
tive thyroid hormone T3 diminish in amatter of hours,whereas variable
levels of levothyroxine (T4), reverse T3, and thyroid stimulating hor-
mone have been observed [43]. A large retrospective cohort of 66,629
donors suggested that T3 treatment improved the haemodynamic pro-
ﬁle of donors and increased the number of organs transplanted [72].
However, the only RCT that has evaluated post-transplantation graft
function failed to show any effects of T3 therapy on liver function [42].
During the screening process, we did identify nine RCTs that assessed
effects of T3 treatment on haemodynamic stability in the donor. Of
these studies, none found any differences in haemodynamic donor pa-
rameters or inotropic needs [42, 73–80]. As a result, the current national
guidelines of National Health Service Blood and Transplant in the UK no
longer advise administration of a rather costly T3 as part of the DBD
donor management.
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Firstly, the number of RCTs that investigated treatment strategies in
the donor and their impact on graft function and survival after trans-
plantation is limited. Furthermore, as our search strategy focused on
donor treatment only, potentially promising treatment strategies of
the graft after procurement and during preservation were excluded
that may be of a pre-transplant treatment potential. In addition, several
studies we did include were performed with a low number of partici-
pants, did not report power calculations or were underpowered to de-
tect changes in the outcome parameters as stipulated in this review.
Consequentially, potential effects on organ function or survival might
have been missed and interpretation of the data from these studies
should be done with caution. Furthermore, we acknowledge that
some outcome parameters, such as plasma bilirubin to assess liver func-
tion or number of organs transplanted in the case of the kidney, are pos-
sibly weakly correlated to organ injury. However, as these endpoints
were assessed in conjunction with other biomarkers, the prognostic
value of these endpoints is strengthened. The few number of studies
also limited us from assessing the risk of publication bias or perform
subgroup analyses. Therefore, drawing conclusions from these studies
is risky, particularly when grouping for meta-analyses was not possible.
Additionally, we found limited studies on lung transplantation, and no
studies on pancreas or intestinal transplantations. Lastly, we realise
that several promising treatment strategies published in relevant ani-
mal models are not included in this article. However, we believe that
these studies were outside the scope of this review as interpretation
of these results are not yet inﬂuential in clinical decision making in de-
ceased donor care.5. Conclusions
The current global shortage of suitable donor organs and often un-
certainty which organ to accept or decline, underlines the need for op-
timisation of deceased donor care. Treatment strategies aim at
reducing the detrimental effects of haemodynamic, hormonal, inﬂam-
matory, andmetabolic disturbances prior to organ retrieval. Better con-
ditioning of the grafts-to-be and reducing, or even preventing, donor-
related injury prior to preservation and transplantation have become
important goals to transplant higher risk donor organs, without
compromising outcomes after transplantation. Unfortunately, current
donor management protocols may vary considerably per centre and
are based on low-level evidence. In this systematic review, we could
not ﬁnd consistent evidence supporting that any individual treatment
that has been tested until nowwill protect donor organs or improve sur-
vival after transplantation. More organised and deﬁned RCTs are re-
quired to identify and validate possible beneﬁts of innovative
treatments before clinical implementation can be recommended as
part of standard donor care. We feel that a concerted action between
professionals in Intensive Care and organ transplantation is needed to
gain better insight and stimulate clinically relevant interventions in
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